Recommendations from the Investigational New Drug/Investigational Device Exemption Task Force of the Clinical and Translational Science Award Consortium: Developing and Implementing a Sponsor-Investigators Training Program

Abstract

Objective

The objective of this study was to provide recommendations for provision of training for sponsor and investigators at Academic Health Centers.

Background

A subgroup of the Investigational New Drug/Investigational Device Exemption (IND/IDE) Task Force of the Clinical and Translational Science Award (CTSA) program Regulatory Knowledge Key Function Committee was assembled to specifically address how clinical investigators who hold an IND/IDE and thus assume the role of sponsor-investigators are adequately trained to meet the additional regulatory requirements of this role.

Methods

The participants who developed the recommendations were representatives of institutions with IND/IDE support programs. Through an informal survey, the task force determined that a variety and mix of models are used to provide support for IND/IDE holders within CTSA institutions. In addition, a CTSA consortium-wide resources survey was used. The participants worked from the models and survey results to develop consensus recommendations to address institutional support, training content, and implementation.

Recommendations

The CTSA IND/IDE Task Force recommendations are as follows: (1) Institutions should assess the scope of Food and Drug Administration–regulated research, perform a needs analysis, and provide resources to implement a suitable training program; (2) The model of training program should be tailored to each institution; (3) The training should specifically address the unique role of sponsor-investigators, and the effectiveness of training should be evaluated regularly by methods that fit the model adopted by the institution; and (4) Institutional leadership should mandate sponsor-investigator training and effectively communicate the necessity and availability of training.

Keywords

Clinical and Translational Science Award regulatory knowledge FDA-regulated research sponsor-investigator Investigational New Drug Investigational Device Exemption Academic Health Center

Get full access to this article

View all access options for this article.

References

Zerhouni

EA.

Clinical research at a crossroads: the NIH roadmap. J Investig Med . 2006; 54 (4): 171–173.

Code of Federal Regulations Title 21 Food and Drugs Chapter I Food and Drug Administration Department of Health and Human Services Subchapter D—Drugs for Human Use Part 312—

Investigational New Drug Application. (21 CFR 312) (Revised as ofApril 1, 2013).

Code of Federal Regulations Title 21 Food and Drugs Chapter I Food and Drug Administration Department of Health and Human Services Subchapter H—Medical Devices Part 812—

Investigational Device Exemptions (21 CFR 812) (Revised as of April 1, 2013).

Heller

, de Melo-Martin

Clinical and Translational Science Awards: can they increase the efficiency and speed of clinical and translational research?

Acad Med . 2009; 84 (4): 424–432.

Berro

, Burnett

, Fromell

, . Support for investigator-initiated clinical research involving investigational drugs or devices: the Clinical and Translational Science Award experience. Acad Med . 2011; 86 (2): 217–223.

Survey conducted by CTSA Consortium Coordinating Center (C4) . Joan E. Adamo and Karen A. Hartman provided domain expertise and guidance in development of the C4 IND/IDE Support survey as part of the CATCHR project. Available at: https://www.ctsacentral.org/catchr/portfolio. Accessed February 4, 2014.

Steinberg

, Rubin

ER.

Commentary: compliance education and training: a need for new responses in clinical research. Acad Med . 2010; 85 (3): 395–397.

Investigational New Drug . 21 CFR §312.53. Selecting investigators and monitors.

Investigational Device Exemption .21 CFR §812.43(a). Selecting investigators and monitors.

10.

ICH Harmonised Tripartite Guideline ; Guideline for Good Clinical Practice E6(R1) Current Step 4 version dated 10 June 1996. (Section 5.6.1).

11.

Investigational New Drug 21 CFR §312.50—59. Subpart D. Responsibilities of Sponsors and Investigators.

12.

Investigational Device Exemption . 21 CFR §812.40—46. Subpart C Responsibilities of Sponsors.

13.

Investigational New Drug 21 CFR §312.60—69. Subpart D. Responsibilities of Sponsors and Investigators.

14.

Investigational Device Exemption 21 CFR §812.100—110. Subpart E Responsibilities of Investigators.

15.

Teo

AR.

The development of clinical research training: past history and current trends in the United States. Acad Med . 2009; 84 (4): 433–438.

16.

Association for the Accreditation of Human Research Protection Programs . AAHRPP Accreditation Standards. Available at: http://www.aahrpp.org/apply/web-document-library/aahrpp-issues-final-revised-accreditation-standards. Accessed February 5, 2014.